Aclaris Therapeutics, Inc.
ACRSHealthcare|Biotechnology|US
$3.90
+0.29 (+8.03%)
Tangible Book / Share
$1.12
Cash / Share
$0.76
Clinical Trials (36)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06374459 Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis | Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer | P1P2 | Recruiting | 152 | RCT, Open-label | Zumsemetinib, Capecitabine, Zoledronic acid, Denosumab |
| NCT07011706 ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis, Atopic | P2 | Active | 110 | RCT, Double-blind | ATI-045, Placebo |
| NCT06648434 MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer | P1 | Recruiting | 51 | Open-label | Zunsemetinib, mFOLFIRINOX |
| NCT03380390 Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea | Rosacea | P4 | Completed | 46 | Open-label | Oxymetazoline HCL 1.0% Cream |
| NCT03487588 An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses | Seborrheic Keratosis | P4 | Completed | 41 | Open-label | A-101 Topical Solution |
| NCT02667288 An Open-Label Safety Study of A-101 Solution | Seborrheic Keratosis | P3 | Completed | 147 | Open-label | A-101 Solution |
| NCT03812510 Safety Study of A-101 Topical Solution for the Treatment of Common Warts | Common Wart | P3 | Completed | 426 | Open-label | A-101 |
| NCT02667275 A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis | Seborrheic Keratosis | P3 | Completed | 487 | RCT, Double-blind | A-101 Solution |
| NCT03687372 Study of A-101 Topical Solution for the Treatment of Common Warts | Common Wart | P3 | Completed | 503 | RCT, Double-blind | A-101 |
| NCT03691831 A Study of A-101 Topical Solution for the Treatment of Common Warts | Common Wart | P3 | Completed | 502 | RCT, Double-blind | Active |
| NCT02667236 A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis. | Seborrheic Keratosis | P3 | Completed | 450 | RCT, Double-blind | A-101 Solution |
| NCT03224598 A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra | Dermatosis Papulosa Nigra | P2 | Completed | 39 | RCT, Open-label | A-101 Topical Solution 40% |
| NCT02260180 Study of A-101 for the Treatment of Seborrheic Keratosis | Seborrheic Keratosis | P2 | Completed | 119 | RCT, Double-blind | A-101 |
| NCT03315689 Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT) | Alopecia Universalis (AU), Alopecia Totalis (AT) | P2 | Completed | 11 | RCT, Double-blind | Vehicle, ATI-50002 |
| NCT02160626 Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis | Seborrheic Keratosis | P2 | Completed | 172 | RCT, Double-blind | A-101 Vehicle, A-101 (40) Topical Solution, A-101 (32.5) Topical Solution |
| NCT05216224 ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) | Hidradenitis Suppurativa | P2 | Completed | 95 | RCT, Double-blind | ATI-450, Placebo oral tablet |
| NCT01986920 Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis | Seborrheic Keratosis (SK) | P1P2 | Completed | 35 | RCT, Double-blind | A-101 25%, A-101 32.5%, A-101 40%, A-101 Vehicle |
| NCT02669862 A Study of A-101 Solution in Subjects With Common Warts. | Common Warts | P2 | Completed | 98 | RCT, Double-blind | A-101 Solution 40, A-101 Solution 45, Vehicle Solution |
| NCT04524858 Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS) | Cryopyrin-Associated Periodic Syndrome | P2 | Terminated | 1 | Open-label | ATI-450 |
| NCT06585202 Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | P2 | Completed | 14 | Open-label | ATI-2138 |
| NCT03551821 Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata | Alopecia Areata, Alopecia Totalis | P2 | Completed | 1 | Open-label | ATI-50002 |
| NCT03585296 A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis | Atopic Dermatitis | P2 | Completed | 22 | Open-label | ATI-502 |
| NCT03148691 A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis | Seborrheic Keratosis | P2 | Completed | 253 | RCT, Double-blind | A-101 |
| NCT03468855 A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo | Vitiligo | P2 | Completed | 34 | Open-label | ATI-50002 topical solution |
| NCT03759340 ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT) | Alopecia Areata, Alopecia Universalis | P2 | Terminated | 56 | Open-label | ATI 502 0.46% Topical Solution |
| NCT04247815 Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA | Rheumatoid Arthritis | P2 | Completed | 25 | RCT, Double-blind | ATI-450, Placebo oral tablet, Methotrexate |
| NCT05432596 Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis | Atopic Dermatitis | P2 | Completed | 250 | RCT, Double-blind | ATI-1777 2.0% w/w, ATI-1777 1.0% w/w, ATI-1777 0.5% w/w, Vehicle |
| NCT03278028 A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts | Common Wart | P2 | Completed | 159 | RCT, Double-blind | A-101 Topical Solution, A-101 Vehicle Solution |
| NCT03354637 A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata | Alopecia Areata | P2 | Terminated | 129 | RCT, Double-blind | ATI-50002 high dose, ATI-50002 low dose, Placebo |
| NCT03495817 A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution | Androgenetic Alopecia | P2 | Completed | 31 | Open-label | ATI-50002 |
| NCT03594227 ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis | Alopecia | P2 | Completed | 87 | RCT, Double-blind | ATI-501 400mg BID (Low dose), ATI-501 600mg BID (Mid dose), ATI-501 800mg BID (High dose), Placebo |
| NCT03210337 A Phase2 of A-101 Topical Solution in Subjects With Common Warts | Common Wart | P2 | Completed | 157 | RCT, Double-blind | A-101 Topical Solution, A-101 Vehicle Solution |
| NCT04598269 Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis | Atopic Dermatitis | P2 | Completed | 50 | RCT, Double-blind | ATI-1777, Vehicle |
| NCT05511519 Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis | Psoriatic Arthritis | P2 | Terminated | 47 | RCT, Double-blind | ATI-450, Placebo Oral Tablet |
| NCT05279417 ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA) | Rheumatoid Arthritis | P2 | Completed | 251 | RCT, Double-blind | ATI-450 50 mg oral tablet BID, Placebo oral tablet, Methotrexate, ATI-450 20 mg oral tablet BID |
| NCT05791474 ATI-2231 in Advanced Solid Tumor Malignancies | Advanced Solid Tumor, Advanced Solid Tumor Malignancies | P1 | Withdrawn | — | Open-label | ATI-2231 |